China Biologic Products Inc (NASDAQ:CBPO) saw a large increase in short interest in the month of April. As of April 28th, there was short interest totalling 1,801,192 shares, an increase of 6.5% from the April 13th total of 1,690,750 shares. Based on an average daily volume of 212,352 shares, the days-to-cover ratio is presently 8.5 days.

Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Friday, May 5th. Jefferies Group LLC set a $128.00 target price on shares of China Biologic Products and gave the company a “buy” rating in a research report on Monday, February 27th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $135.00 target price on shares of China Biologic Products in a research report on Friday, March 3rd.

Shares of China Biologic Products (NASDAQ:CBPO) traded up 1.78% during mid-day trading on Friday, hitting $111.00. 94,937 shares of the stock traded hands. The firm has a market capitalization of $3.02 billion, a P/E ratio of 28.75 and a beta of 1.78. The company’s 50 day moving average is $111.29 and its 200 day moving average is $110.89. China Biologic Products has a one year low of $96.99 and a one year high of $137.38.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.11. China Biologic Products had a net margin of 30.63% and a return on equity of 19.61%. The company had revenue of $77.60 million for the quarter, compared to the consensus estimate of $76.61 million. During the same period last year, the company posted $0.74 EPS. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. On average, equities analysts expect that China Biologic Products will post $5.09 EPS for the current fiscal year.

In other news, CEO David Gao sold 116,653 shares of the business’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $100.63, for a total transaction of $11,738,791.39. Following the transaction, the chief executive officer now owns 449,396 shares in the company, valued at approximately $45,222,719.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Zhijing Cbpo Liu sold 7,500 shares of the business’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $116.49, for a total transaction of $873,675.00. Following the transaction, the insider now owns 10,969 shares in the company, valued at approximately $1,277,778.81. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 144,153 shares of company stock worth $14,628,066. Insiders own 2.68% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Dumac Inc. bought a new stake in China Biologic Products during the fourth quarter worth $100,000. Oppenheimer Asset Management Inc. bought a new stake in China Biologic Products during the first quarter worth $156,000. Eqis Capital Management Inc. increased its stake in China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares during the last quarter. Trexquant Investment LP bought a new stake in China Biologic Products during the fourth quarter worth $462,000. Finally, Nomura Holdings Inc. bought a new stake in China Biologic Products during the first quarter worth $463,000. Institutional investors own 69.86% of the company’s stock.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/19/china-biologic-products-inc-cbpo-short-interest-update.html.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

5 Day Chart for NASDAQ:CBPO

Receive News & Ratings for China Biologic Products Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc and related companies with MarketBeat.com's FREE daily email newsletter.